University of Edinburgh academics will work with Belgian biotech firm to develop new cancer medicines
University of Edinburgh academics have agreed a two-year collaborative partnership with Belgian biotechnology firm Galapagos to develop new cancer medicines.
The partnership, initially for two years with a view to developing a longer-term collaboration, will provide Galapagos with access to models and research from the Edinburgh Cancer Discovery Unit to develop medicines targeting novel, proprietary modes of action.
Galapagos said gaining this insight into the mechanism of action of particular compounds is critical in improving the effectiveness of those compounds in combating various forms of cancer.
The partnership is being led by Edinburgh BioQuarter, a joint venture between Alexandria Real Estate Equities, Inc, the NHS, the University of Edinburgh and Scottish Enterprise.
Dr Neil Carragher, principal investigator at the Edinburgh Cancer Research Centre, said: “Working with our team, Galapagos will be able to access a wide range of advanced cancer models and technical capabilities established within the Edinburgh Cancer Discovery Unit, as well as the team’s outstanding knowledge and expertise.”
Dr Mike Capaldi, commercialisation director at Edinburgh BioQuarter, said: “Following on from the collaborative agreement with GSK at the end of 2011, this new partnership with Galapagos demonstrates industry’s growing awareness of the depth of world-class research being undertaken here in Edinburgh.
“It’s also further evidence of the strength of partnership we enjoy with both the University of Edinburgh’s research community and the bio-pharmaceutical industry.”